- Home
- FENC vs FTHY Comparison
FENC vs FTHY Comparison
Compare FENC & FTHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | FTHY |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 493.5M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FENC | FTHY |
|---|---|---|
| Price | $10.88 | $12.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 239.3K | 104.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.93% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $176.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $12.93 |
| 52 Week High | $13.25 | $14.71 |
Technical Indicators
Market Signals| Indicator | FENC | FTHY |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 32.27 |
| Support Level | $10.88 | N/A |
| Resistance Level | $11.28 | $13.75 |
| Average True Range (ATR) | 0.50 | 0.10 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 28.44 | 14.89 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.